Objective To analyze the efficacy of hepatic arterial infusion chemotherapy(HAIC)sequential drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE)in the treatment of liver metastases from colorectal cancer.Methods 86 patients with colorectal cancer liver metastasis admitted to multiple centers from September 2022 to September 2023 were selected and divided into a control group(43 cases)and an experimental group(43 cases)according to the random number table method.The control group was treated with HAIC,and the experimental group was treated with HAIC sequential DEB-TACE.The clinical data and the changes of tumor markers and liver function indexes before and after treatment were compared between the two groups,and the short-term and long-term efficacy was evaluated,and the adverse reactions were recorded.Results After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 199,carbohydrate antigen 242,aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase and γ-glutamyl transpeptidase in the two groups decreased(P<0.05),and those in the experimental group were lower than the control group(P<0.05).The proportion of repeated treatment in the experimental group was lower than that in the control group(P<0.05).The objective remission rate and disease control rate in the experimental group were 60.00%and 82.50%respectively,which were higher than 30.95%and 61.90%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the control group and the experimental group(P>0.05).The results of Kaplan-Meier survival curve showed that the overall survival rate and progression-free survival rate of the experimental group were higher than those of the control group(P<0.05).Conclusions HAIC sequential DEB-TACE can effectively remove tumor cells and improve liver function in patients with colorectal can-cer liver metastasis,and it has good clinical efficacy and can prolong the survival time of patients.

Objective To analyze the efficacy of hepatic arterial infusion chemotherapy(HAIC)sequential drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE)in the treatment of liver metastases from colorectal cancer.Methods 86 patients with colorectal cancer liver metastasis admitted to multiple centers from September 2022 to September 2023 were selected and divided into a control group(43 cases)and an experimental group(43 cases)according to the random number table method.The control group was treated with HAIC,and the experimental group was treated with HAIC sequential DEB-TACE.The clinical data and the changes of tumor markers and liver function indexes before and after treatment were compared between the two groups,and the short-term and long-term efficacy was evaluated,and the adverse reactions were recorded.Results After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 199,carbohydrate antigen 242,aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase and γ-glutamyl transpeptidase in the two groups decreased(P<0.05),and those in the experimental group were lower than the control group(P<0.05).The proportion of repeated treatment in the experimental group was lower than that in the control group(P<0.05).The objective remission rate and disease control rate in the experimental group were 60.00%and 82.50%respectively,which were higher than 30.95%and 61.90%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the control group and the experimental group(P>0.05).The results of Kaplan-Meier survival curve showed that the overall survival rate and progression-free survival rate of the experimental group were higher than those of the control group(P<0.05).Conclusions HAIC sequential DEB-TACE can effectively remove tumor cells and improve liver function in patients with colorectal can-cer liver metastasis,and it has good clinical efficacy and can prolong the survival time of patients.

The long-acting cabotegravir and rilpivirine injection regimen（CAB+RPV regimen）is the first approved long-acting antiretroviral therapy（ART）for HIV in China，administered once every two months. This regimen provides an innovative alternative to daily oral ART，benefiting virologically suppressed patients. Several large clinical-studies have shown that the CAB+RPV regimen achieves comparable virologic suppression and safety to daily oral regimens，while significantly enhancing patient satisfaction. Based on international and domestic HIV/AIDs guidelines and clinical evidence，this consensus offers expert recommendations on patient selection，clinical management，and key communication strategies for healthcare providers to support the effective use of this regimen，aiming to improve quality of life for people living with HIV and accumulate domestic clinical experience with this advanced treatment approach.

The clinical manifestations of tuberculous meningoencephalitis(TBME)are varied,and diagnostic tests for Mycobacterium tuberculosis show limited sensitivity and specificity,often failing to provide timely diagnostic support,which can delay prompt treatment.Reports on anti-neurexin-3α antibody-mediated autoimmune encephalitis remain scarce,and there have been no documented cases of TBME overlapping with anti-neurexin-3α antibody-associated encephalitis either domestically or internationally.This article presents a case treated at our hospital to contribute insights for improving the diagnosis and treatment of such conditions in the future.The patient,a middle-aged woman,presented with a one-month history of headache and incoherent speech,along with one day of left-sided limb weakness.Lumbar puncture results revealed significantly elevated cerebrospinal fluid(CSF)pressure,an increased lymphocyte count,and reduced glucose and chloride levels.Enhanced MRI showed multiple intracranial lesions,basal meningeal enhancement,and marked hydrocephalus,supporting an initial diagnosis of TBME.Concurrently,both blood and CSF tests were positive for anti-neurexin-3α antibodies.After comprehensive treatment,including anti-tuberculosis therapy,high-dose immunoglobulin,and corticosteroids,the patient's clinical symptoms,CSF findings,and MRI results improved,and she was discharged.

The clinical manifestations of tuberculous meningoencephalitis(TBME)are varied,and diagnostic tests for Mycobacterium tuberculosis show limited sensitivity and specificity,often failing to provide timely diagnostic support,which can delay prompt treatment.Reports on anti-neurexin-3α antibody-mediated autoimmune encephalitis remain scarce,and there have been no documented cases of TBME overlapping with anti-neurexin-3α antibody-associated encephalitis either domestically or internationally.This article presents a case treated at our hospital to contribute insights for improving the diagnosis and treatment of such conditions in the future.The patient,a middle-aged woman,presented with a one-month history of headache and incoherent speech,along with one day of left-sided limb weakness.Lumbar puncture results revealed significantly elevated cerebrospinal fluid(CSF)pressure,an increased lymphocyte count,and reduced glucose and chloride levels.Enhanced MRI showed multiple intracranial lesions,basal meningeal enhancement,and marked hydrocephalus,supporting an initial diagnosis of TBME.Concurrently,both blood and CSF tests were positive for anti-neurexin-3α antibodies.After comprehensive treatment,including anti-tuberculosis therapy,high-dose immunoglobulin,and corticosteroids,the patient's clinical symptoms,CSF findings,and MRI results improved,and she was discharged.

The long-acting cabotegravir and rilpivirine injection regimen（CAB+RPV regimen）is the first approved long-acting antiretroviral therapy（ART）for HIV in China，administered once every two months. This regimen provides an innovative alternative to daily oral ART，benefiting virologically suppressed patients. Several large clinical-studies have shown that the CAB+RPV regimen achieves comparable virologic suppression and safety to daily oral regimens，while significantly enhancing patient satisfaction. Based on international and domestic HIV/AIDs guidelines and clinical evidence，this consensus offers expert recommendations on patient selection，clinical management，and key communication strategies for healthcare providers to support the effective use of this regimen，aiming to improve quality of life for people living with HIV and accumulate domestic clinical experience with this advanced treatment approach.